The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Dec. 24, 2019
Applicant:

Neogap Therapeutics Ab, Stockholm, SE;

Inventors:

Hans Gronlund, Lidingö, SE;

Ola Winqvist, Uppsala, SE;

Assignee:

NEOGAP THERAPEUTICS AB, Stockholm, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 40/11 (2025.01); A61K 40/428 (2025.01); A61K 40/46 (2025.01); C12N 5/0636 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/892 (2018.08); C12N 2710/20011 (2013.01); C12N 2710/20023 (2013.01); C12N 2710/20034 (2013.01);
Abstract

The present invention provides a method for the expansion of HPV immunogen specific T cells, comprising the steps of: i. providing a phagocytosable particle comprising a core and a human papillomavirus (HPV) immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein; ii. providing APCs; iii. contacting the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs; iv. providing T-cells that have been harvested from a subject; v. contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells. The invention further provides an expanded population of therapeutically useful T-cells and their use in the treatment or prevention of cancer, particularly HPV positive cancers.


Find Patent Forward Citations

Loading…